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IntroductIon
Obesity, a highly prevalent major public health problem, is 
associated with increased mortality and morbidity, including 
an increased risk of type 2 diabetes mellitus and cardiovascular 
disease, physical disabilities, sleep apnea, and reduced quality 
of life (1). When achieved by medically recommended proce-
dures, weight loss (WL) is associated with reduced morbidities 
in obese persons (2). Beyond surgery, long-term weight reduc-
tions much greater than 3–6 kg remain elusive (3). Hence, gen-
erating additional medical treatment options is a priority.
Phentermine hydrochloride is a sympathomimetic amine 
approved by the US Food and Drug Administration (FDA) in 
1959 with a dose range of up to 37.5 mg/day for short-term 
obesity treatment. Phentermine stimulates increased hypoth-
alamic release of norepinephrine with no detectable effect 
on  serotonin  (4).  Topiramate,  a  fructose  monosaccharide 
derivative with sulphamate functionality, was approved for the 
treatment of epilepsy in 1996 and the prevention of migraine 
in 2004. Randomized controlled trials (RCTs) show that topira-
mate monotherapy produces WL among obese individuals of 
~6–8 kg at 24 weeks and improvements in lipids, glycemic con-
trol, and blood pressure (BP) (5–7). However, topiramate has 
been associated with adverse events (AEs) that may limit its 
use as a single agent at optimal doses for WL. With respect to 
possible mechanisms for the WL effects of topiramate, animal 
experiments suggest that topiramate-induced WL results from 
increased energy expenditure, decreased energetic efficiency, 
and decreased caloric intake (8–10). A significant factor asso-
ciated with topiramate-induced WL in humans appears to be 
decreased caloric intake (11–13). However, consistent with 
animal findings, reduction in caloric intake does not appear 
to fully explain the observed WL (11,12); thus, as suggested 
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by animal studies, topiramate-induced WL in humans may 
be also related to other mechanisms, such as increased energy 
expenditure or decreased energy efficiency.
Controlled-release  phentermine/topiramate  (PHEN/TPM 
CR) is an investigational WL therapy combining immediate-
release phentermine and controlled-release topiramate given 
in a single daily morning dose. The top dose of PHEN/TPM 
CR contains phentermine 15 mg (expressed as free-base) and 
topiramate 92 mg. PHEN/TPM CR contains lower doses of 
these components than are currently marketed or have been 
studied for monotherapy in obesity (6,14). Each of the individ-
ual components has published dose-related efficacy, tolerability, 
and AE data (15–17). The combination’s efficacy in WL exceeds 
the maximal response achieved with either individual agent 
alone at equivalent doses (18), which plausibly results from each 
component targeting multiple mechanisms that impact energy 
balance. The goal in developing this combination therapy was 
to use the dose of each respective agent that provided the great-
est level of WL efficacy while minimizing tolerability concerns.
Methods and Procedures
design overview
A double-blind, parallel-group design was used with three arms: pla-
cebo (n = 514), PHEN/TPM CR 3.75/23 mg (n = 241), and PHEN/TPM 
CR 15/92 mg (n = 512). After screening, all eligible patients underwent 
a blinded 4-week postrandomization titration period and 52 weeks at 
randomized dose. All interventions were added to a standardized life-
style program. Total treatment duration was 56 weeks.
settings and participants
Subjects were enrolled beginning in November 2007 at 91 US sites, 
consisting of clinical practices, clinical trial sites, and academic centers. 
The last subject completed all study visits in May 2009. At every site, 
institutional review board approval and written informed consent were 
obtained. Eligibility criteria included age 18–70 years, BMI ≥35 kg/m2 
(no upper limit), triglycerides ≤200 mg/dl with treatment of 0–1 lipid-
lowering medication, BP ≤140/90 mm Hg with treatment of 0–2 anti-
hypertensive medications, and fasting serum glucose level ≤110 mg/dl. 
For detailed entry criteria, see Supplementary Appendix 3 online.
randomization and interventions
Patients were randomized and stratified by gender via a pseudo-ran-
dom number generator constrained to a 2:1:2 allocation ratio. This 
allocation ratio was designed to increase the power of the safety anal-
ysis by having more patients receive placebo and by having the high-
est dose used. All study participants, study physicians, site staff, and 
sponsor representatives involved in the study conduct were blinded 
to patient assignment until after the trial was complete. There was an 
independent, unblinded data and safety monitoring board. The study 
drug and placebo were visually indistinguishable. Treatment was ini-
tiated with a 4-week blinded titration period (typically recommended 
with clinical topiramate use to minimize AEs), starting with PHEN/
TPM CR 3.75/23 or matched placebo and thereafter increased weekly 
by 3.75/23 mg increments to the assigned dose. Following titration to 
assigned dose, patients were evaluated for an additional 52 weeks with 
monthly clinic visits. All patients were provided with standardized 
lifestyle counseling, based on the LEARN Manual (19) and advised 
to follow a 500-kcal daily reduction in dietary intake, increased water 
consumption, and increased physical activity.
outcomes and follow-up
Outcomes of interest were percent, absolute, and categorical body-WL 
as well as numerous metabolic and cardiovascular outcomes. Patients 
were weighed using a calibrated digital scale, and waist circumference 
(WC) was measured by trained study personnel at each visit. BP meas-
urements were obtained using a calibrated sphygmomanometer with 
appropriately sized cuff. Fasting blood samples were drawn at baseline 
and then at weeks 4, 8, 16, 28, and 56 and analyzed in a single central 
reference laboratory (Medpace Reference Laboratories, Cincinnati, 
OH). AEs were monitored at each visit with occurrence date, severity, 
relationship to study drug, action taken with respect to study drug, 
and outcome. Depression and suicidality were also assessed in detail 
(see Supplementary Appendix 2 online). As recommended else-
where (20), patients who discontinued treatment were encouraged 
to continue with data assessments through study completion, even 
though they were no longer taking the drug.
statistical analyses
Power  analysis.  Based  on  standard  deviations  for  percent  WL 
observed in a previous PHEN/TPM CR study (21), this study provided 
>95% power at the two-tailed 0.05 α-level to reject the null hypoth-
esis of no treatment-placebo difference if the population difference was 
~2% to 3% of body weight (BW).
Primary efficacy analyses. The primary efficacy measure was per-
cent WL at end of study, analyzed once as a continuous variable and 
then as a dichotomous variable with cut-off points at 5%, 10%, and 15% 
of BW. Secondary efficacy measures were change in WC, systolic BP, 
diastolic BP, fasting triglycerides, total cholesterol, low-density lipo-
protein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
total cholesterol/HDL ratio, and fasting serum glucose. Gender was 
included as a covariate in all models since it was used as a stratification 
factor.
For analysis of percent WL as a dependent variable, three main analy-
ses were performed (listed as analyses A–C in Table 1) and are reported 
in detail with additional sensitivity analyses (analyses D–F in Table 1) 
in Supplementary Appendixes 1–3 online. Analysis A, the analysis 
prespecified in the study protocol, is an intent-to-treat (ITT) analysis 
according to FDA standards (22). Note that this analysis included data 
from patients who discontinued the drug but remained in the study 
and continued with data assessments through study completion, even 
though they were no longer taking the drug.
Analysis B was a prespecified secondary per protocol–based analysis 
that was included to facilitate assessment of the experience in patients 
who reported using the study drug or placebo for the full intended treat-
ment course. It included only patients for whom end-point data were 
available and who reported taking their study drug/placebo within 7 days 
before final end-point measurement. Again, the analysis of covariance 
model described in Table 1 was used.
Analysis C was an ITT analysis as defined by Lachin (23) that included 
all randomized patients. To accommodate missing data, multiple imputa-
tion was used as described in Table 1 (for further detail, refer to Elobeid 
et al., (24)).
For analyses with percent weight change as a dichotomous outcome, 
the three analyses described above were used except that analysis of 
covariance was replaced by a corresponding logistic regression with 
the same covariates.
Sensitivity analyses for primary efficacy end points. To test the 
robustness of findings to variations in data analytic procedures, sev-
eral additional efficacy analyses (analyses D–F in Table 1) on percent 
WL were conducted. For the mixed model described in analysis E of 
Table 1, a random-effects regression model with treatment, gender, 
baseline, and time as covariates was used, where time was modeled 
as continuous and calculated from first dose date. Random intercepts 
and slopes were estimated and an unstructured residual covariance 
matrix was specified. Results of these analyses are described in Sup-
plementary Table S2 online.
Analyses for secondary efficacy end points. For all other efficacy 
measures, reported analyses correspond to analyses A–C described in 332  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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Table 1, substituting change (or percent change for some variables as 
indicated in results section) in the dependent variable of interest for 
percent WL and baseline values of that dependent variable for base-
line BW.
Safety analyses. All AE-preferred terms (defined by MedDRA coding 
dictionary version 10.1) with a frequency of 5% or more in any treat-
ment group or those that occurred significantly more often with active 
treatment than placebo (at a two-tailed nominal 0.05 α-level) are listed 
in Table 4. Due to concerns with past WL drugs (25), we conducted 
extensive  depression  and  suicidality  assessments  using  the  Patient 
Health  Questionnaire  (PHQ-9)  and  Columbia  Suicidality  Severity 
Rating Scale (C-SSRS) instruments (see Supplementary Appendix 2 
online).
results
Baseline characteristics
Baseline data are in Table  2. Groups were not significantly 
different on any baseline variable. Overall, mean age was 42.7 
years, mean BMI was 42.0 kg/m2, and 83% were female, with 
substantial representation of black patients (16–18%). Means 
for BP, fasting glucose, triglycerides, and HDL cholesterol 
did not meet established thresholds indicative of increased 
cardiometabolic disease risk (26).
subject disposition
As shown in Figure 1, 59.9% of randomized patients com-
pleted the study regardless of whether they continued taking 
the assigned drug/placebo (52.9% placebo, 61.0% PHEN/TPM 
CR 3.75/23, 66.4% PHEN/TPM CR 15/92; P < 0.0001 for dif-
ference), and 53.7% reported taking the assigned study drug/
placebo for the full intended treatment course (46.9% placebo, 
57.3% PHEN/TPM CR 3.75/23, 58.8% PHEN/TPM CR 15/92; 
P = 0.0003 for difference). Most common reasons for discon-
tinuation were lost to follow-up or withdrawal of consent 
(more common in placebo than active groups) or AEs (more 
common in active than placebo groups). Overall discontinua-
tions were lower in patients receiving active treatments.
Weight loss
Patients in the 15/92 group lost significantly more weight 
than  patients  in  the  3.75/23  group  who  in  turn  lost  sig-
nificantly  more  weight  than  patients  receiving  placebo   
(P < 0.0001 for all comparisons; see Figure 2 and Table 3), 
regardless of analysis used. Using the prespecified ITT-last 
observation carried forward (LOCF) (Analysis A), patients 
table 1  efficacy analyses conducted for percent weight loss as a continuous outcome
Analysis Name
Patients  
included
Missing data management 
procedure
Statistical analysis  
applied
A Prespecified  
ITT-LOCF
All randomized patients who 
received at least one dose of 
drug/placebo and had at least 
one postrandomization weight 
measurement
LOCF ANCOVA with percent weight loss 
as dependent variable, sex and 
baseline body weight as covariates, 
and treatment assignment as the 
independent variable
B Completers  
only
All randomized patients who had a 
week 56 measurement and received 
at least one dose of drug/placebo 
treatment within 7 days of their week 
56 measurement
None Same as for prespecified ITT-LOCF
C Randomized-
ITT-MI
All randomized patients MI with m = 5 imputations per 
analysis. Treatment assignment, 
sex, and all measurements of the 
efficacy variable under study were 
used in a two-step imputation 
processa
Same as for prespecified ITT-LOCF
D Modified-ITT-MI All randomized patients who 
received at least one dose of 
drug/placebo and had at least 
one postrandomization weight 
measurement
Same as for prespecified ITT-LOCF
E Modified-ITT-MM All randomized patients who 
received at least one dose of 
drug/placebo and had at least 
one postrandomization weight 
measurement
Not applicable (see above for details 
of mixed model procedures)
Random-effects regression model 
with subject-specific intercepts and 
slopes (see above and footnoteb for 
details)
F On drug LOCF All randomized patients who 
received at least one dose of 
drug/placebo and had at least 
one postrandomization weight 
measurement
Last observation within 7 days of 
last dose of drug/placebo carried 
forward
Same as for prespecified ITT-LOCF
(100 × (baseline weight − weight at end point)/baseline weight).
ANCOVA, analysis of covariance; ITT, intent-to-treat; LOCF, last observation carried forward; MI, multiple imputation; MM, mixed model.
aFirst, sufficient data were imputed to impose a monotone missing data pattern via a Markov chain Monte Carlo algorithm. Subsequently, any remaining missing data 
were imputed assuming a monotone missing data pattern and using Rubin’s regression method (44). The complete imputed datasets were then analyzed via ANCOVA 
as described in Table 1. The separate results from the imputed datasets were then pooled into single estimates and tested as described by Schafer (45).
bMore specifically, a linear mixed model was used with simple linear fixed effects, random intercept, and slopes with unstructured covariance, G in SAS Proc Mixed 
documentation, and within-subject covariance σ2I, R in SAS Proc Mixed documentation.obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  333
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table 2  Baseline data by treatment condition
Placebo (n = 514) PHEN/TPM CR 3.75/23 (n = 241) PHEN/TPM CR 15/92 (n = 512)
Age, years
  Mean (s.d.) 43.0 (11.76) 43.0 (10.96) 41.9 (12.21)
Sex, n (%)
  Female 425 (82.7) 201 (83.4) 424 (82.8)
  Male 89 (17.3) 40 (16.6) 88 (17.2)
Ethnicity, n (%)
  Hispanic/Latino 74 (14.4) 29 (12.0) 81 (15.8)
  Non-Hispanic/Latino 440 (85.6) 212 (88.0) 431 (84.2)
Race, n (%)
  White 413 (80.4) 192 (79.7) 408 (79.7)
  Black 93 (18.1) 39 (16.2) 93 (18.2)
  American Indian or Alaskan native 6 (1.2) 2 (0.8) 7 (1.4)
  Asian American 3 (0.6) 2 (0.8) 1 (0.2)
  Native Hawaiian or other Pacific Islander 2 (0.4) 1 (0.4) 2 (0.4)
  Other 4 (0.8) 5 (2.1) 7 (1.4)
Weight, kg
  n 513 240 511
  Mean (s.d.) 115.8 (21.46) 118.5 (21.85) 115.2 (20.66)
Height, cm
  n 513 240 511
  Mean (s.d.) 165.9 (9.11) 166.6 (8.57) 165.6 (8.62)
BMI, kg/m2
  n 513 240 511
  Mean (s.d.) 42.0 (6.15) 42.6 (6.50) 41.9 (6.04)
Waist circumference, cm
  n 513 240 511
  Mean (s.d.) 120.5 (13.92) 121.7 (15.15) 120.1 (14.63)
Low-density lipoprotein cholesterol, mg/dl
  n 512 240 511
  Mean (s.d.) 121.3 (32.02) 122.5 (32.96) 119.8 (30.06)
High-density lipoprotein cholesterol, mg/dl
  n 513 240 511
  Mean (s.d.) 49.5 (13.09) 50.2 (11.20) 49.8 (11.72)
Total cholesterol, mg/dl
  n 513 240 511
  Mean (s.d.) 194.7 (36.36) 196.1 (36.08) 192.5 (33.77)
Triglycerides, mg/dl
  n 513 240 511
  Mean (s.d.) 118.8 (39.20) 116.7 (40.12) 114.0 (37.24)
Fasting serum glucose, mg/dl
  n 510 240 511
  Mean (s.d.) 93.0 (8.70) 93.8 (9.11) 93.0 (9.47)
Systolic blood pressure, mm Hg
  n 513 240 511
  Mean (s.d.) 121.8 (11.45) 122.5 (11.08) 122.0 (11.58)
Diastolic blood pressure, mm Hg
  n 513 240 511
  Mean (s.d.) 77.2 (7.85) 77.8 (7.46) 77.4 (7.69)
Heart rate, bpm
  n 513 240 511
  Mean (s.d.) 73.2 (8.84) 72.3 (9.18) 73.2 (9.57)
History of depression, n (%) 81 (15.8) 47 (19.6) 74 (14.8)
Antidepressant drug use, n (%) 68 (13.2) 36 (14.9) 65 (12.7)
History of depression and/or antidepressant drug 
use, n (%)
105 (20.4) 57 (23.7) 95 (18.6)
BPM, beats per minute; PHEN/TPM CR, controlled-release phentermine/topiramate.334  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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receiving 15/92, 3.75/23, and placebo lost 10.9%, 5.1%, and 
1.6%  of  BW,  respectively.  Moreover,  completers  (Table  3, 
Analysis  B  and  Supplementary  Table  S2  and  Figure  S1 
online) lost 14.4% of BW on 15/92 and 6.7% on 3.75/23 and 
only 2.1% on placebo. Statistical assumption testing suggested 
appropriateness of the models, with all sensitivity analyses 
(Analyses C–F) yielding confirmatory findings (Table 3 and 
Supplementary Appendix 1 and Table S2 online). We also 
conducted the baseline observation carried forward analy-
ses (27), and although point estimates changed, conclusions 
about statistical significance and direction of effects remained 
unchanged (data not shown).
When analyzed as dichotomous data, regardless of cut-off 
point (5%, 10%, or 15% of BW), a higher proportion of patients 
in the 15/92 group exceeded threshold than did patients in the 
3.75/23 group, whose proportion exceeded that of placebo 
patients (P < 0.05 for all comparisons). In the prespecified-ITT-
LOCF (Analysis A), percentages of patients losing ≥5%, ≥10%, 
and ≥15% of BW were, respectively, 66.7%, 47.2%, and 32.3% 
on 15/92; 44.9%, 18.8%, and 7.3% on 3.75/23; and 17.3%, 7.4%, 
and 3.4% on placebo (all comparisons P < 0.05). Among com-
pleters, percentages of patients losing ≥5%, ≥10%, and ≥15% 
of BW were, respectively, 83.5%, 67.7%, and 48.1% on 15/92; 
59.1%, 27.7%, and 12.4% on 3.75/23; and 25.5%, 13.0%, and 
5.9% on placebo (all comparisons P < 0.0001).
We tested whether results differed by baseline BMI by repeat-
ing Analysis A after categorizing patients by baseline BMI and 
then testing for interaction between baseline BMI category and 
treatment. The interaction was not significant (P = 0.8056), 
indicating that results did not significantly differ by baseline 
BMI (Figure 2).
secondary end point analysis
The 15/92 group had significantly greater least-squares mean 
changes, relative to placebo, in WC, systolic BP, diastolic BP, 
glucose, triglycerides, total cholesterol/HDL ratio, total cho-
lesterol, LDL cholesterol, and HDL cholesterol. The 3.75/23 
group had numerically, but not always statistically significant, 
greater least-squares mean changes compared with placebo, in 
all these variables (Table 3).
Inclusion/exclusion
Screened failures (n = 855)
Patients screened (N = 2,122)
criteria violation:
criteria violation:
Withdrew consent:
Lost to follow-up:
Placebo (n = 514)
Adverse events: 20
0
0
3
0
5
1
2
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
Adverse events: 16
92
3
10
2
15
92
12
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
Adverse events: 16
31
1
4
1
3
31
7
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
Adverse events: 36
63
1
5
14
0
43
10
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
Adverse events: 6
0
0
0
0
3
0
0
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
Adverse events: 29
0
0
1
0
5
3
1
Lost to follow-up:
Restricted meds:
Noncompliance:
Pregnancy:
Lack of efficacy:
Withdrew consent:
Other:
PHEN/TPM CR 3.75/23 (n = 241) PHEN/TPM CR 15/92 (n = 512)
D/C study drug but
completed study (n = 39)*
D/C study and
study drug (n = 172)†
D/C study and
study drug (n = 94)†
D/C study and
study drug (n = 242)†
D/C study drug but
completed study (n = 9)*
D/C study drug but
completed study (n = 31)*
Completed study on
study drug (n = 301)
Completed study on
study drug (n = 138)
Completed study on
study drug (n = 241)
Randomization
677
77
28
24
49 Other:
Figure 1  Patient disposition. After screening, all eligible patients underwent 56 weeks of treatment; 4-week blinded, postrandomization titration 
period, followed by 52 weeks at randomized dose. *Reason for discontinuation as reported while subject was receiving study drug; †Reason for study 
discontinuation. Subjects were able to discontinue study drug and study for different reason, however, reason was often the same. When they differed, the 
final reason for discontinuation from the study was used. D/C, discontinued; Meds, medications; PHEN/TPM CR, controlled-release phentermine/topiramate.obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  335
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safety analyses
Table 4 lists AEs that occurred at a frequency of 5% or higher 
in any treatment group or occurred at a significantly higher 
frequency in the 15/92 group than placebo. The most common 
AEs occurring more often with 15/92 treatment than placebo 
included paresthesia, dry mouth, constipation, dysgeusia, and 
insomnia. Other less frequent events occurring more commonly 
with  15/92  treatment  were  depression,  irritability,  alopecia, 
anxiety, disturbance in attention, and hypoesthesia. Serious AE 
(SAE) rates were the same across treatment groups: 13 (2.5%) 
with placebo, 6 (2.5%) with 3.75/23, and 13 (2.5%) with 15/92.
Most AEs reported were mild in severity (Supplementary 
Table S3 online). AEs most often resulting in treatment dis-
continuation in the 15/92 group were insomnia, irritability, 
anxiety, headache, disturbance in attention, depression, dry 
mouth, and nephrolithiasis. The exact numbers and percent-
ages of AE-related dropouts were 43 (8.4%) for placebo, 27 
(11.3%) for 3.75/23, and 82 (16.0%) for 15/92.
Drug-related SAEs occurred in 2 (0.4%) patients treated 
with placebo, 1 (0.4%) patient treated with 3.75/23, and 1 
(0.2%) patient treated with 15/92. The SAEs reported as drug-
related in the placebo group included chest pain and pulmo-
nary embolism, both of which resulted in discontinuation of 
study drug. The SAE reported in the 3.75/23 group was chole-
lithiasis that resolved following a 1-week interruption of treat-
ment, and one patient treated with 15/92 was diagnosed with 
myelogenous leukemia ~6 months after starting treatment and 
discontinued the study due to this event. These data should be 
viewed with the understanding that very few SAEs have been 
reported as drug-related and that investigators’ assessments of 
causality are speculative.
Change from baseline in heart rate was also assessed. By week 
56, mean heart rate had decreased 0.2 bpm in placebo, 0.3 bpm 
on 3.75/23 (P = 0.9552 vs. placebo), and increased 1.2 bpm on 
15/92 (P = 0.0830 vs. placebo). Both doses of PHEN/TPM CR 
resulted in a decrease in serum bicarbonate (mean changes in 
mEq/l: −0.3 for placebo, −1.6 for 3.75/23, and −1.7 for 15/92); 
significant reductions (<17 mEq/l at two consecutive visits) 
occurred in only 3 (1.3%) patients receiving 3.75/23, 4 (0.8%) 
patients receiving 15/92, and none receiving placebo.
In addition, depressive symptoms were assessed using the 
PHQ-9 questionnaire, and suicidality (ideation and behavior) 
was assessed using the C-SSRS (Supplementary Appendix 2 and 
Table S1 online). Change in mean PHQ-9 total score indicated 
improvement in depressive symptoms over time in all treatment 
groups, but no significant differences among groups. There was 
no significantly increased suicide risk as defined and assessed by 
the C-SSRS in patients treated with PHEN/TPM CR compared 
with placebo. Neither suicidal behavior nor suicidal ideation 
with an intent to act were reported at any time after treatment 
initiation, and rates of suicidal ideation without intent to act 
were comparable to rates seen in placebo-treated patients.
There were 15 pregnancies in women exposed to PHEN/
TPM CR. Among these, there were three spontaneous abor-
tions, three elective abortions, and nine healthy live births. No 
congenital malformations were observed.
dIscussIon
Three salient points emerge from this RCT. First, PHEN/
TPM CR caused WL in obese patients. Compared with pla-
cebo, both doses of PHEN/TPM CR yielded significantly 
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table 4  adverse events with a frequency of ≥5% in any treatment group or differing significantly in frequency between placebo 
and either treatment group
Placebo (n = 513) PHEN/TPM CR 3.75/23 (n = 240) PHEN/TPM CR 15/92 (n = 511)
Adverse event n (%) n (%) P valuea n (%) P value
Paresthesia 10 (1.9) 10 (4.2) 0.0902 96 (18.8) <0.0001
Dry mouth 19 (3.7) 16 (6.7) 0.0931 87 (17.0) <0.0001
Constipation 35 (6.8) 19 (7.9) 0.6495 72 (14.1) 0.0001
Upper respiratory tract 
infection
56 (10.9) 38 (15.8) 0.0594 63 (12.3) 0.4962
Headache 52 (10.1) 25 (10.4) 0.8979 61 (11.9) 0.3709
Nasopharyngitis 37 (7.2) 30 (12.5) 0.0199 46 (9.0) 0.3050
Dysgeusia 5 (1.0) 3 (1.3) 0.7145 43 (8.4) <0.0001
Insomnia 25 (4.9) 12 (5.0) 1.0000 40 (7.8) 0.0553
Nausea 24 (4.7) 14 (5.8) 0.4811 37 (7.2) 0.0875
Sinusitis 28 (5.5) 18 (7.5) 0.3269 37 (7.2) 0.2515
Dizziness 21 (4.1) 7 (2.9) 0.5371 29 (5.7) 0.2498
Back pain 26 (5.1) 13 (5.4) 0.8607 28 (5.5) 0.7817
Bronchitis 22 (4.3) 16 (6.7) 0.2100 28 (5.5) 0.3885
Cough 18 (3.5) 8 (3.3) 1.0000 26 (5.1) 0.2218
Influenza 24 (4.7) 18 (7.5) 0.1264 26 (5.1) 0.7740
Depression 6 (1.2) 8 (3.3) 0.0770 24 (4.7) 0.0007
Diarrhea 23 (4.5) 12 (5.0) 0.7151 24 (4.7) 0.8825
Fatigue 17 (3.3) 12 (5.0) 0.3094 23 (4.5) 0.3385
Irritability 3 (0.6) 4 (1.7) 0.2178 23 (4.5) <0.0001
Vision blurred 16 (3.1) 15 (6.3) 0.0501 23 (4.5) 0.2582
Alopecia 5 (1.0) 5 (2.1) 0.3034 22 (4.3) 0.0008
Anxiety 6 (1.2) 7 (2.9) 0.1288 19 (3.7) 0.0084
Disturbance in attention 3 (0.6) 1 (0.4) 1.0000 18 (3.5) 0.0007
Hypoesthesia 4 (0.8) 2 (0.8) 1.0000 17 (3.3) 0.0039
Dry eye 4 (0.8) 2 (0.8) 1.0000 12 (2.3) 0.0470
Paresthesia oral 2 (0.4) 1 (0.4) 1.0000 11 (2.2) 0.0123
Dry skin 1 (0.2) 0 (0.0) 1.0000 8 (1.6) 0.0208
Anorexia 0 (0.0) 3 (1.3) 0.0321 7 (1.4) 0.0075
Serum bicarbonate 
decreased
1 (0.2) 0 (0.0) 1.0000 7 (1.4) 0.0381
Feeling jittery 1 (0.2) 3 (1.3) 0.0980 7 (1.4) 0.0381
Amenorrhea 0 (0.0) 0 (0.0) N/A 6 (1.2) 0.0152
Aphasia 0 (0.0) 0 (0.0) N/A 6 (1.2) 0.0152
Back injury 0 (0.0) 3 (1.3) 0.0321 5 (1.0) 0.0306
Serum potassium 
decreased
0 (0.0) 1 (0.4) 0.3187 5 (1.0) 0.0306
Hypogeusia 0 (0.0) 1 (0.4) 0.3187 5 (1.0) 0.0306
Parosmia 0 (0.0) 1 (0.4) 0.3187 5 (1.0) 0.0306
Osteoarthritis 0 (0.0) 4 (1.7) 0.0101 2 (0.4) 0.2488
Rhinitis 0 (0.0) 4 (1.7) 0.0101 1 (0.2) 0.4990
Preferred terms defined by MedDRA Coding Dictionary version 10.1. At a two-tailed nominal α-level of 0.05. No adjustment for multiple testing has been performed.
N/A, not applicable; PHEN/TPM CR, controlled-release phentermine/topiramate.
aBy Fisher’s exact test for comparison to placebo. For each preferred term, two Fisher’s exact tests for 2 × 2 contingency tables were conducted, one to compare 3.75/23 
with placebo and one to compare 15/92 with placebo.340  VOLUME 20 NUMBER 2 | fEBRUaRy 2012 | www.obesityjournal.org
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greater 1-year WL, with a greater proportion of patients los-
ing more than 5%, 10%, or 15% of baseline BW. Results were 
consistent regardless of analytic method employed. Patients 
treated with PHEN/TPM CR 15/92 and 3.75/23 lost 10.9% 
and 5.1% of BW, respectively, when analyzed as ITT-LOCF, 
compared with 1.6% WL on placebo and 14.4% and 6.7% 
WL in completers-only analyses compared with 2.1% WL 
with placebo. Among patients who completed the course of 
15/92, 48.1% lost ≥15% of BW, 67.7% lost ≥10%, and 83.5% 
lost ≥5%. Significant WL also occurred early; patients treated 
with 15/92 lost between 8% and 10% of BW after 3 months 
of treatment.
Second, WL induced by PHEN/TPM CR was accompanied 
by improvements in many cardiovascular and metabolic risk 
factors, such as WC, systolic BP, and total cholesterol/HDL 
cholesterol ratio in both doses. PHEN/TPM CR 15/92 treat-
ment was also associated with significant improvements in 
diastolic BP, fasting glucose, LDL cholesterol, HDL cholesterol, 
and total cholesterol.
Third, certain AEs (paresthesia, dry mouth, constipation, 
and dysgeusia) occurred at a higher frequency with 15/92 treat-
ment, with twice (16.2% vs. 8.4%) as many patients treated with 
15/92 compared with placebo withdrawing due to one or more 
AE. An indication of tolerability can be obtained from the AE 
data. The most common AEs associated with PHEN/TPM CR 
treatment were paresthesia, dry mouth, constipation, dysgeu-
sia, and insomnia; however, none of these events caused study 
discontinuation in more than 1% of patients. Mood-related 
(depression,  anxiety,  and  irritability)  and  cognition-related 
(disturbance in attention) AEs occurred at higher frequen-
cies among patients receiving 15/92. Mood assessments with 
standardized rating scales (PHQ-9) showed an improvement in 
mood-related symptoms overall (see Supplementary Table S1 
online). The low incidence of treatment-emergent depression in 
this trial should be viewed in the context of exclusion of patients 
with substantial depressive symptoms at study entry (PHQ-9 
score of >10 was an exclusion criterion, and the mean (s.d.) 
PHQ-9 score of 2.8 (2.8) was low, suggesting minimal depres-
sive symptoms). However, the study allowed participation of 
patients with a self-reported history of depression, patients 
with adequately controlled depression based on PHQ-9 scores, 
and those on stable doses of antidepressants. Neither suicidal 
behavior nor suicidal ideation with intent to act was reported 
at any time after treatment initiation. There was no significantly 
increased suicide risk, as defined and assessed by the C-SSRS, in 
patients treated with PHEN/TPM CR compared with placebo.
In this study, there were no birth defects among infants 
whose mothers were exposed to study treatment. However, 
given the FDA’s recent reclassification of topiramate use during 
pregnancy (FDA has recently added a warning about increased 
risk of cleft lip and cleft palate with topiramate and its preg-
nancy category has now been changed to category D) and the 
general belief that WL during pregnancy is not wise, the use 
of PHEN/TPM during pregnancy is not recommended. For 
more and recent information on this topic, refer to Mølgaard-
Nielsen et al. (28).
Phentermine has been associated with elevations in BP (29). 
In this study, PHEN/TPM CR led to reduced BP. Phentermine 
has also been associated with elevations in heart rate (29). 
Here, there was an increase in resting heart rate seen in the 
15/92 subgroup (1.2 bpm above the baseline value of 73.2 bpm; 
P = 0.083 compared with placebo), whereas heart rate was 
unaltered in the 3.75/23 subgroup (a decrease of 0.3 bpm from 
baseline; P = 0.955 compared with placebo).
This heart rate increase in the 15/92 group is plausibly attrib-
utable to the sympathomimetic action of phentermine, given 
that increased heart rates have been observed in patients treated 
with the higher doses of phentermine monotherapy approved for 
short-term therapy of obesity (29). In the 15/92 treatment group, 
the increased heart rate was accompanied by a reduction of 
2.9 mm Hg in systolic BP (ITT-LOCF; P < 0.0001 compared with 
placebo) and a 1.5 mm Hg decrease in diastolic BP (P = 0.0002 
compared with placebo). By comparison, in the SCOUT Trial, the 
sibutramine treatment group exhibited a significantly increased 
heart rate combined with a significant elevation in BP compared 
with placebo (30). In terms of overall cardiac risk, larger future 
studies can test the hypothesis that the beneficial effects of PHEN/
TPM CR on weight, BP, lipids, and glycemic measures mitigate 
any AEs on heart rate.
Although most pharmaceutical obesity RCTs include BMIs 
ranging from 27–40, or 45 at most, this study included patients 
with class II and III obesity (BMI ≥35 kg/m2) without any 
upper BMI limit. WL magnitude resulting from PHEN/TPM 
CR administration was estimated to be consistent across this 
broader BMI spectrum (ranging from 35.0–78.7). This finding 
refutes a common notion that nonsurgical treatments are not 
efficacious among extremely obese persons. For example, the 
National Heart, Lung, and Blood Institute guidelines on obes-
ity treatment state, “Extremely obese persons often do not ben-
efit from the more conservative treatments for WL and weight 
maintenance” (31). Our results show that this is not necessarily 
true. This finding is germane to the 14% of the US adult popu-
lation classified as “extremely obese” (32).
A study limitation was the 40% dropout rate (47.1%, 39.0%, 
and 33.6% for patients receiving placebo, 3.75/23, and 15/92, 
respectively). This dropout rate is consistent with what one 
would expect at 56 weeks in obesity trials based on a published 
meta-analytic prediction equation (24) and lower than the 
50% dropout recently reported with two other phase 3 obesity 
RCTs (33,34). Although our approach to retaining subjects, 
even if they discontinued the drug, and our use of ITT anal-
yses with established missing data management procedures 
may have mitigated these high dropout rates, retention of 
patients in WL trials of 1 year or longer remains challenging. 
Nevertheless, we used several different ways of handling the 
missing data, all of which obtained confirmatory results. These 
statistical methods rest on fewer and less restrictive assump-
tions than do complete case analyses (35). Moreover, retention 
rate was significantly higher with active treatment compared 
with placebo. Although speculative, this may have been due 
in part to greater WL efficacy in the treatment groups. Greater 
early WL may provide tangible encouragement for patients to obesity | VOLUME 20 NUMBER 2 | fEBRUaRy 2012  341
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pursue lifestyle guidance and has been shown to be associ-
ated with greater success in WL programs (36). There were 
other limitations, including the overrepresentation of women 
(83%). Further studies with larger groups of men may be 
informative. The trial included mostly white persons and 
many participants did not have significant obesity-associated 
comorbid diseases. A publication of another RCT of PHEN/
TPM CR covers this broader population (37). Furthermore, 
the  study  report  herein  excluded  patients  with  recurrent 
depression, although patients on stable antidepressants were 
allowed. In future studies, determining the extent to which 
WL effects of this combination therapy are maintained for 
2 years and beyond will also be informative. It will also be 
valuable to monitor potential adverse outcomes for periods 
beyond 1 year. Gathering information regarding efficacy and 
safety, including rate-pressure product of this drug therapy 
in patients with these and other significant comorbidities, in 
future studies may be valuable.
Currently  available  pharmacologic  agents  generally  offer 
efficacy of ≤9% body-WL (3,38), and although modest WL is 
associated with improvements in weight-related comorbidities 
(39,40), greater benefits are seen with increased WL (39,41). 
Some bariatric surgery procedures are associated with mean WL 
of ~33% before some weight gain tends to reoccur (42). Data 
suggest that lap-banding results in ~22% WL after 24 months 
(43). PHEN/TPM CR 15/92 was associated with 14.4% WL in 
study completers (Analysis B) at 1 year, arguably the relevant 
comparison to surgical treatment. This appears to represent a 
result between that of other available pharmacologic agents and 
that of lap-banding, although randomized head-to-head com-
parison studies would be required before any definitive state-
ments about relative efficacy of treatments can be made.
In this RCT of PHEN/TPM CR, both 3.75/23 and 15/92 in 
conjunction with lifestyle modification produced statistically 
significant WL compared with placebo. PHEN/TPM CR 15/92 
provided WL and concomitant improvement in comorbidities 
that exceeds weight losses reported at 1 year for other currently 
available pharmaceutical treatments. PHEN/TPM CR demon-
strated dose-dependent beneficial effects on weight and meta-
bolic variables with no evidence of SAEs induced by treatment.
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